Pasithea Therapeutics wins Nasdaq extension to regain $1 minimum bid compliance

PUBT · 2d ago
Pasithea Therapeutics wins Nasdaq extension to regain $1 minimum bid compliance
  • Pasithea Therapeutics received a Nasdaq notice of non-compliance with the $1 minimum bid price rule.
  • Nasdaq granted a 180-day extension to regain compliance, setting a new deadline of Feb. 16, 2027.
  • Failure to meet the requirement by the deadline could trigger a delisting notice, with an option to appeal to a hearings panel.
  • Management flagged a potential reverse stock split as a compliance measure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-092672), on August 21, 2026, and is solely responsible for the information contained therein.